Inventor · disambiguated record
Markus Hossbach
Also filed as: HOSSBACH MARKUS
20 granted patents·18 pending applications·86 citations·filing 2009–2024
93Inventor score
Files withVOYAGER THERAPEUTICS INC9ALIGOS THERAPEUTICS INC5ARROWHEAD PHARMACEUTICALS INC4MINA THERAPEUTICS LTD4Neurovision Pharma GmbH4
Top patents by PatentIndex Score
38 records- 0196US10920227B2Compositions and methods of treating amyotrophic lateral sclerosis (ALS)VOYAGER THERAPEUTICS INC·Filed 2020·Granted Feb 16, 2021·8 cites·22 claims
- 0295US11549110B2Modified short interfering nucleic acid (siNA) molecules and uses thereofALIGOS THERAPEUTICS INC·Filed 2022·Granted Jan 10, 2023·5 cites·30 claims
- 0394US11542506B2Compositions and methods of treating amyotrophic lateral sclerosis (ALS)VOYAGER THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·3 cites·30 claims
- 0494US10597660B2Compositions and methods of treating amyotrophic lateral sclerosis (ALS)VOYAGER THERAPEUTICS INC·Filed 2015·Granted Mar 24, 2020·11 cites·27 claims
- 0593US8809293B2Compositions and methods for inhibiting gene expression of hepatitis B virusCHIN DANIEL·Filed 2012·Granted Aug 19, 2014·45 cites·17 claims
- 0692US12129469B2Modified short interfering nucleic acid (siNA) molecules and uses thereofALIGOS THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·30 claims
- 0789US11752181B2Compositions and methods of treating Huntington's diseaseVOYAGER THERAPEUTICS INC·Filed 2018·Granted Sep 12, 2023·4 cites·21 claims
- 0889USRE48345ECompositions and methods for inhibiting gene expression of hepatitis B virusARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Dec 8, 2020·3 cites·69 claims
- 0988US2025146000A1Compositions and methods of treating amyotrophic lateral sclerosis (als)VOYAGER THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1084US12123002B2Compositions and methods of treating amyotrophic lateral sclerosis (ALS)VOYAGER THERAPEUTICS INC·Filed 2022·Granted Oct 22, 2024·0 cites·20 claims
- 1181US10912790B2C/EBP alpha saRNA compositions and methods of useMINA THERAPEUTICS LTD·Filed 2016·Granted Feb 9, 2021·2 cites·23 claims
- 1278US2023332153A1Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses ThereofALIGOS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1377US2024415868A1Compositions and methods for treating huntington's diseaseVOYAGER THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1476US12454691B2Modified short interfering nucleic acid (siNA) molecules and uses thereofALIGOS THERAPEUTICS INC·Filed 2022·Granted Oct 28, 2025·0 cites·29 claims
- 1576US11213541B2Antisense-oligonucleotides as inhibitors of TGF-R signalingNeurovision Pharma GmbH·Filed 2015·Granted Jan 4, 2022·2 cites·5 claims
- 1675US11965163B2HNF4a saRNA compositions and methods of useMINA THERAPEUTICS LTD·Filed 2021·Granted Apr 23, 2024·0 cites·12 claims
- 1775US2024226203A9Compositions and methods of treating huntington's diseaseVOYAGER THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1872US11920134B2Compositions and methods for inhibiting expression of RRM2 genesARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Mar 5, 2024·0 cites·21 claims
- 1970US2022364096A1Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses ThereofALIGOS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2069US8946176B2Compositions and methods for inhibiting expression of RRM2 genesBOYLAN JOHN FREDERICK·Filed 2011·Granted Feb 3, 2015·1 cites·18 claims
- 2168US10619160B2Compositions and methods for inhibiting expression of RRM2 genesARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Apr 14, 2020·0 cites·21 claims
- 2267US11162099B2HNF4A saRNA compositions and methods of useMINA THERAPEUTICS LTD·Filed 2018·Granted Nov 2, 2021·0 cites·4 claims
- 2365US11951121B2Compositions and methods for treating Huntington's diseaseVOYAGER THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2024·0 cites·29 claims
- 2465US2022143071A1Antisense-oligonucleotides as inhibitors of tgf-r signalingNeurovision Pharma GmbH·Filed 2021·Application pending·0 cites
- 2563US10363266B2Antisense-oligonucleotides as inhibitors of TGF-R signalingNeurovision Pharma GmbH·Filed 2015·Granted Jul 30, 2019·1 cites·5 claims
- 2662US2015113670A1Compositions and Methods for Inhibiting Expression of RRM2 GenesARROWHEAD RES CORP·Filed 2014·Application pending·0 cites
- 2761US9938531B2Compositions and methods for inhibiting expression of RRM2 genesARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 10, 2018·0 cites·18 claims
- 2860US2021187007A1C/ebp alpha sarna compositions and methods of useMINA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2954US2019314401A1Antisense-oligonucleotides as inhibitors of tgf-r signalingNeurovision Pharma GmbH·Filed 2019·Application pending·0 cites
- 3048US2011119781A1Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor GenesBRAMLAGE BIRGIT·Filed 2009·Application pending·0 cites
- 3148US2010124547A1Compositions and methods for inhibiting expression of factor vii genesBRAMLAGE BIRGIT·Filed 2009·Application pending·0 cites
- 3241US2015291956A1Rna targeted to beta cateninPHASERX INC·Filed 2013·Application pending·0 cites
- 3341US2011152349A1Compositions and methods for inhibiting expression of il-18 genesGEICK ANKE·Filed 2010·Application pending·0 cites
- 3441US2015337318A1Rna targeted to c-metPHASERX INC·Filed 2013·Application pending·0 cites
- 3538US2011112176A1Compositions and methods for inhibiting expression of kif10 genesBOYLAN JOHN FREDERICK·Filed 2010·Application pending·0 cites
- 3638US2011196016A1Compositions and Methods for Inhibiting Expression of IKK2 GenesGEICK ANKE·Filed 2011·Application pending·0 cites
- 3732US2011020300A1Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genesGENENTECH INC·Filed 2010·Application pending·0 cites
- 3828US2010197773A1Compositions and methods for inhibiting expression of ptp1b genesBRAMLAGE BIRGIT·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Markus Hossbach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →